PBAC's latest decision on Dtpa-hepb-ipv-hib vaccine: Recommended (2015). Considered for Primary vaccination series against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b in infants at 2, 4 and 6 months of age.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Healthy infants receiving primary vaccination series at 2, 4 and 6 months of age.
Therapy area
Vaccines
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
Surrogate
Pivotal trial size
3,240 patients
Key trials
A3L11, A3L12, A3L17, A3L24, A3L21, A3L27
Comparator
Infanrix Hexa
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design. Estimated to be cost-neutral to the NIP.